아토피 피부염 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 약제 클래스별, 투여 경로별, 지역별 세분화 및 경쟁 구도(2020-2030년)

The Global Atopic Dermatitis Drugs Market, valued at USD 14.52 Billion in 2024, is projected to experience a CAGR of 8.83% to reach USD 24.12 Billion by 2030. The global atopic dermatitis drugs market comprises pharmaceutical interventions designed to manage atopic dermatitis, a chronic inflammatory skin condition characterized by intense pruritus and eczematous lesions. Key drivers supporting market expansion include the increasing global prevalence of the disease, significant advancements in understanding disease pathophysiology leading to the development of novel targeted therapies, and improved diagnostic capabilities facilitating earlier treatment initiation.

Key Market Drivers

The increasing global prevalence of atopic dermatitis profoundly influences the pharmaceutical market by continually expanding the patient population requiring advanced therapeutic solutions. This chronic inflammatory skin condition manifests across all demographics, generating persistent demand for effective drug interventions capable of managing diverse disease severities. The expanding patient pool necessitates a broader portfolio of medications to alleviate symptoms and address underlying immunological dysregulation.

Key Market Challenges

The high cost associated with advanced therapeutic agents, particularly biologics and Janus kinase inhibitors, significantly impedes the growth of the global atopic dermatitis drugs market. These substantial expenses create considerable reimbursement hurdles for healthcare systems and often result in restricted patient access to these critical medications. This limitation directly slows market expansion by preventing a broader patient population from initiating or continuing effective advanced treatments, despite clinical need. The financial burden impacts both individual patients, who may face high out-of-pocket costs, and payers, who implement stringent coverage criteria.

Key Market Trends

Personalized Medicine and Biomarker-Guided Therapies

This trend fundamentally reshapes the global atopic dermatitis drugs market by fostering treatments tailored to individual patient profiles. Leveraging biomarkers and genetic insights, this precision approach aims to enhance therapeutic efficacy and minimize adverse reactions, optimizing patient outcomes. The Canadian Dermatology Foundation, in 2025, supported this direction by offering Innovation Grants of up to $100,000 over two years for dermatology research projects. Furthermore, Eli Lilly announced in March 2024 results from a lebrikizumab study specifically for people with skin of color and moderate-to-severe atopic dermatitis, evaluating 50 patients with darker skin tones. This signifies the market's evolution towards precise, demographic-specific therapeutic solutions.

Key Market Players

• Abbvie, Inc.
• Bausch Health Companies Inc.
• Nestle India Limited
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Evelo Biosciences, Inc.
• Cara Therapeutics Inc.
• Bristol-Myers Squibb Company

Report Scope:

In this report, the Global Atopic Dermatitis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Atopic Dermatitis Drugs Market, By Drug Class:

• Biologics
• PDE4 Inhibitors
• Corticosteroids
• Calcineurin Inhibitors

Atopic Dermatitis Drugs Market, By Route of Administration:

• Topical
• Injectable
• Oral

Atopic Dermatitis Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Atopic Dermatitis Drugs Market.

Available Customizations:

Global Atopic Dermatitis Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Atopic Dermatitis Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Biologics, PDE4 Inhibitors, Corticosteroids, Calcineurin Inhibitors)
  • 5.2.2. By Route of Administration (Topical, Injectable, Oral)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Atopic Dermatitis Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Route of Administration
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Atopic Dermatitis Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Route of Administration
  • 6.3.2. Canada Atopic Dermatitis Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Route of Administration
  • 6.3.3. Mexico Atopic Dermatitis Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Route of Administration

7. Europe Atopic Dermatitis Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Route of Administration
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Atopic Dermatitis Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Route of Administration
  • 7.3.2. France Atopic Dermatitis Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Route of Administration
  • 7.3.3. United Kingdom Atopic Dermatitis Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Route of Administration
  • 7.3.4. Italy Atopic Dermatitis Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Route of Administration
  • 7.3.5. Spain Atopic Dermatitis Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Route of Administration

8. Asia Pacific Atopic Dermatitis Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Route of Administration
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Atopic Dermatitis Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Route of Administration
  • 8.3.2. India Atopic Dermatitis Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Route of Administration
  • 8.3.3. Japan Atopic Dermatitis Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Route of Administration
  • 8.3.4. South Korea Atopic Dermatitis Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Route of Administration
  • 8.3.5. Australia Atopic Dermatitis Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Route of Administration

9. Middle East & Africa Atopic Dermatitis Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Route of Administration
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Atopic Dermatitis Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Route of Administration
  • 9.3.2. UAE Atopic Dermatitis Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Route of Administration
  • 9.3.3. South Africa Atopic Dermatitis Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Route of Administration

10. South America Atopic Dermatitis Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Route of Administration
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Atopic Dermatitis Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Route of Administration
  • 10.3.2. Colombia Atopic Dermatitis Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Route of Administration
  • 10.3.3. Argentina Atopic Dermatitis Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Route of Administration

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Atopic Dermatitis Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abbvie, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bausch Health Companies Inc.
• 15.3. Nestle India Limited
• 15.4. Pfizer Inc.
• 15.5. Regeneron Pharmaceuticals Inc.
• 15.6. Evelo Biosciences, Inc.
• 15.7. Cara Therapeutics Inc.
• 15.8. Bristol-Myers Squibb Company

16. Strategic Recommendations

17. About Us & Disclaimer